NEW YORK, Aug. 7, 2017 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against the board
of directors of NxStage Medical, Inc. ("NxStage" or the "Company")
(NASDAQ: NXTM) concerning the proposed acquisition of the Company
by Fresenius Medical Care ("Fresenius").
Under the terms of the offer, Fresenius would acquire NxStage in
a transaction valued at approximately $2
billion. Pursuant to the deal, NxStage stockholders
will receive $30.00 in cash per
share. At least one Wall Street analyst set a price target
for NxStage stock of $33.00 per
share.
Our investigation concerns whether the NxStage board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company
stockholders.
If you own NxStage shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Benjamin I. Sachs-Michaels,
Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-nxstage-medical-inc-300500457.html
SOURCE Harwood Feffer LLP